| Year | Citation |
|---|---|
| 2018 | Mikkelsen, K., Hallam, K., Stojanovska, L., & Apostolopoulos, V. (180101). Yeast based spreads improve anxiety and stress. Journal of Functional Foods, 40 (471-476). |
| 2017 | Prakash, M. D., Tangalakis, K., Antonipillai, J., Stojanovska, L., Nurgali, K., & Apostolopoulos, V. (170601). Methamphetamine: Effects on the brain, gut and immune system. Pharmacological Research, 120 (60-67). |
| 2017 |
Lourbopoulos, A., Deraos, G., Matsoukas, M. T., Touloumi, O., Giannakopoulou, A., Kalbacher, H., Grigoriadis, N., Apostolopoulos, V., & Matsoukas, J. (170101). Cyclic MOG |
| 2017 |
Apostolopoulos, V., Deraos, G., Matsoukas, M. T., Day, S., Stojanovska, L., Tselios, T., Androutsou, M. E., & Matsoukas, J. (170101). Cyclic citrullinated MBP |
| 2016 | Apostolopoulos, V. (160601). Vaccine delivery methods into the future. Vaccines, 4(2), |
| 2015 | Day, S., Tselios, T., Androutsou, M. E., Tapeinou, A., Frilligou, I., Stojanovska, L., Matsoukas, J., & Apostolopoulos, V. (150101). Mannosylated linear and cyclic single amino acid mutant peptides using a small 10 amino acid linker constitute promising candidates against multiple sclerosis. Frontiers in Immunology, 6(APR), |
| 2013 |
Vassilaros, S., Tsibanis, A., Tsikkinis, A., Pietersz, G. A., McKenzie, I. FC., & Apostolopoulos, V. (131101). Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1. Immunotherapy, 5(11), (1177-1182). doi: 10.2217/imt.13.126 |
| 2009 | Apostolopoulos, V. (090301). Peptide-based vaccines for cancer: Are we choosing the right peptides?. Expert Review of Vaccines, 8(3), (259-260). |
| 2008 | Katsara, M., Yuriev, E., Ramsland, P. A., Deraos, G., Tselios, T., Matsoukas, J., & Apostolopoulos, V. (080801). Mannosylation of mutated MBP83-99 peptides diverts immune responses from Th1 to Th2. Molecular Immunology, 45(13), (3661-3670). |
| 2000 | Corper, A. L., Stratmann, T., Apostolopoulos, V., Scott, C. A., Garcia, K. C., Kang, A. S., Wilson, I. A., & Teyton, L. (000421). A structural framework for deciphering the link between I-A(g7) and autoimmune diabetes. Science, 288(5465), (505-511). |
Key details
Areas of expertise
- Immunology
- Protein crystallography
- Medicinal chemistry
- Cellular and molecular biology
- Extensive translational research expertise with development of drugs and vaccines
Not available to supervise research students
Available for media queries
About Vasso Apostolopoulos
Professor Vasso Apostolopoulos received her PhD majoring in immunology in 1995 from the University of Melbourne, and the Advanced Certificate in Protein Crystallography from Birkbeck College, University of London.
Her expertise is multi-disciplinary with extensive expertise in immunology, x-ray crystallography, medicinal chemistry, cellular biology, molecular biology. She has extensive translational research expertise with development of drugs and vaccines.
Vasso was a Chief Scientific Officer for 4Gvaccines, is on the board, and consults for, a number of pharmaceutical companies worldwide, and is the Director of VAConsulting Services. She was the head of the Immunology and Vaccine Unit at the Austin Research Institute and at the Burnet Institute; the Immunology Program Leader in the Centre for Chronic Disease at Victoria University; and is the Mechanisms and Interventions in Health and Disease Program Leader at the Institute for Health and Sport, Victoria University. She is currently the interim Vice President (Research) at Victoria University.
Professor Vasso Apostolopoulos is a world-renowned researcher who has been recognised with over 100 awards for the outstanding results of her research. Most notable are the Premier’s Award for Medical Research, Young Australian of the Year (Vic), Greek Australian of the Year, Woman of the Year. She was named as one of the most successful Greeks abroad by the prestigious Times magazine.
Vasso was the first in the world to develop the concept of immunotherapy for cancer in the early 1990s, which today is used by hundreds of labs around the world. Immunotherapy aims to boost specific immune cells and program them to kill cancer cells; it was used by Vasso to develop the world’s first breast cancer vaccine with phase I, II and III clinical trials completed. Of note, one of the studies now has long-term follow-up data showing that 20 years later those injected with the vaccine remain cancer free. It has been licensed to an Australian pharmaceutical company.
Using immunotherapy, Vasso has also developed the world’s first ovarian cancer vaccine, which attracted the investment by a pharmaceutical company and has been commercialised in the Middle East. Committed to the wide-ranging benefits of immunotherapy, Vasso has applied this approach to other diseases including a vaccine for multiple sclerosis (which will undergo human clinical trials early in 2019). Most recently, Vasso’s work has been awarded a research grant to develop a vaccine for type-1 diabetes.
Qualifications
- PhD majoring in immunology, University of Melbourne, Australia, 1995
- Advanced certificate in Protein Crystallography, Birkbeck College, University of London, (Yr)
Key publications
Journal article (showing 10 of 305)
Research funding for the past 5 years
Please note:
- Funding is ordered by the year the project commenced and may continue over several years.
- Funding amounts for contact research are not disclosed to maintain commercial confidentiality.
- The order of investigators is not indicative of the role they played in the research project.
2019
|
Vitamin B and Mental Health
From: The Thelma and Paul Constantinou Foundation - Donation
For period: 2019-2020
|
$45,000 |
|
Novel Breast Cancer Markers
From: The Thelma and Paul Constantinou Foundation - Donation
For period: 2019-2020
|
$45,000 |
2018
|
Characterisation of Blood-Derived Stem Cells
From: Surecell Australia Pty Ltd
Investigators: Dr Dimitrios Kiatos, Aspr Kulmira Nurgali
For period: 2018-2019
|
Not disclosed |
|
Preventing a T1D Progression via a Tolerance Inducing Vaccine
From: Juvenile Diabetes Research Foundation Australia
Investigators: Prof Friedrich De courten
For period: 2018-2020
|
Not disclosed |
2017
|
Anti-bacterial properties of phytolin.
From: The Product Makers (TPM) Australian Pty Ltd
Investigators: Prof Lilian Stojanovska
For period: 2017-2018
|
$18,291 |
2016
|
The Effects of Phytolin on Inflammation and Cancer
From: Department of Industry, Innovation and Science (Commonwealth), The Product Makers (TPM) Australian Pty Ltd
Investigators: Prof Lilian Stojanovska
For period: 2016-2017
|
Not disclosed |
|
Part 1 - Master Research Services Agreement
From: Vianex S.A.
For period: 2016-2018
|
$1,317,644 |
2015
|
Part 2: Multiple Sclerosis Program in Australia - MS Immunotherapeutics using MBP
From: Vianex S.A.
For period: 2015-2019
|
$300,000 |
|
Vitamin B and effects on depression
From: Cooper Foundation
For period: 2015-2015
|
$20,000 |
Supervision of research students at VU
Not available to supervise research students
Available for media queries
Currently supervised research students at VU
| No. of students | Study level | Role |
|---|---|---|
| 3 | Masters by Research | Principal supervisor |
| 5 | PhD | Associate supervisor |
| 6 | PhD | Principal supervisor |
Currently supervised research students at VU
| Students & level | Role |
|---|---|
| Masters by Research (3) | Principal supervisor |
| PhD (5) | Associate supervisor |
| PhD (6) | Principal supervisor |
Completed supervision of research students at VU
| No. of students | Study level | Role |
|---|---|---|
| 3 | PhD | Associate supervisor |
| 1 | PhD | Principal supervisor |
| 1 | Masters by Research | Associate supervisor |
Completed supervision of research students at VU
| Students & level | Role |
|---|---|
| PhD (3) | Associate supervisor |
| PhD (1) | Principal supervisor |
| Masters by Research (1) | Associate supervisor |
Careers
Details of this Researcher's career are currently unavailable.
